Star Therapeutics

Star Therapeutics is a private, late clinical-stage biotech founded in 2018 and headquartered in South San Francisco, California. The company is developing novel antibody therapies with an initial focus on bleeding disorders, led by its pivotal Phase 3 candidate, VGA039, which has shown promising early data. With a leadership team experienced in first-in-class antibody development and over $300 million in funding, Star is positioning itself as a potential leader in hemostatic therapeutics while exploring broader applications for its platform.

Antibody innovation platform focused on novel biology and 'pipeline-in-a-product' strategy, engineering monoclonal antibodies against overlooked targets to treat multiple diseases.

In VWD, competition includes plasma-derived and recombinant factor concentrates (e.g., from Takeda, CSL Behring). The broader hemophilia market is highly competitive with factor replacements, bispecific antibodies (e.g., Hemlibra), and gene therapies. Star's differentiation lies in VGA039's novel subcutaneous, universal hemostatic mechanism.